DHA tablets for the Miscarriage MAMS trial come from Strides Pharma
- University of Birmingham
- West Midlands
- Below threshold - without competition
- 21 January 2025 to 25 April 2025
The University of Birmingham bought DHA tablets from Strides Pharma as trial medicine for the Miscarriage MAMS trial.
The trial medicine was supplied in packs of 28 capsules. The university awarded the order directly, without a competition.
The three-month contract was worth £61,740. It started in January 2025 and was due to end in April 2025.
- What
- Aseptic compounding, specials and contract pharmaceutical manufacturing
- Supplier
- Strides Pharma
- Value
- £61,740
- How it was bought
- Below threshold - without competition
- Dates and next
- Jan 2025 to Apr 2025